Cyclosporin twice or three times daily dosing in pediatric transplant patients - It is not the same!

Pediatric Transplantation

Volumn 10, Issue 8, 2006, Pages 953-956

  Filler, Guido ^a   De Barros, Viviane Rocha ^b   Jagger, Justin E ^a   Christians, Uwe ^c  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b HOSPITAL DA CRIANÇA SANTO ANTÔNIO   (Brazil)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

AUC monitoring pediatric patients; Cyclosporin; Immunosuppressive dose regimens; Renal transplantation; Therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; FOCAL GLOMERULOSCLEROSIS; GRAFT REJECTION; HEART GRAFT; HUMAN; KIDNEY GRAFT; MALE; MEAN RESIDENCE TIME; MICROEMULSION; NEPHROTOXICITY; RECIPIENT; RISK FACTOR; SCHOOL CHILD; WILCOXON SIGNED RANKS TEST;

ADOLESCENT; AREA UNDER CURVE; CHILD; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; RETROSPECTIVE STUDIES;

EID: 33750591844     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00592.x     Document Type: Article

References (11)

1. WILLIAMS D, HARAGSIM L. Calcineurin nephrotoxicity. Adv Chronic Kidney Dis 2006: 13: 47-55.
2. FANTA S, BACKMAN JT, SEIKKU P, HOLMBERG C, HOPPU K. Cyclosporine A monitoring - How to account for twice and three times daily dosing. Pediatr Nephrol 2005: 20: 591-596.
3. HOYER PF. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group. Pediatr Transplant 1998: 2: 35-39.
4. BUCHLER M, JOHNSTON A. Seeking optimal prescription of cyclosporine ME. Ther Drug Monit 2005: 27: 3-6.
5. GHOSN J, LAMOTTE C, AIT-MOHAND H, et al. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2004: 17: 209-214.
6. MARZOLINI C, BUCLIN T, DECOSTERD LA, BIOLLAZ J, TELENTI A. Nelfinavir plasma levels under twice-daily and three-timesdaily regimens: High interpatient and low intrapatient variability. Ther Drug Monit 2001: 23: 394-398.
7. FILLER G, LATHIA A, LEBLANC C, CHRISTIANS U. Unexpectedly high exposure of enteric-coated mycophenolate sodium on once-daily dosing. Pediatr Nephrol 2006: 21: 1206-1208.
8. FELIPE CR, SILVA HT JR, MACHADO PG, GARCIA R, MOREIRA SR, PESTANA JO. Time-dependent changes in cyclosporine exposure: Implications for achieving target concentrations. Transpl Int 2003: 16: 494-503.
9. CHRISTIANS U, STROM T, ZHANG YL, et al.. Active drug transport of immunosuppressants: New insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 2006: 28:39-44.
10. CUMMINS CL, JACOBSEN W, BENET LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002: 300: 1036-1045.
11. CUMMINS CL, SALPHATI L, REID MJ, BENET LZ. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: Studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther 2003: 305: 306-314.